Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-28T20:15:34.120Z Has data issue: false hasContentIssue false
  • English
  • Français

Síntomas depresivos durante el mantenimiento con buprenorfina frente a metadona: hallazgos de un ensayo controlado distribuido al azar en la dependencia de opioides

Published online by Cambridge University Press:  12 May 2020

Angela J. Dean ,
James Bell ,
Macdonald J. Christie  and
Richard P. Mattick
Angela J. Dean
Affiliation:
Departamento de Psiquiatría, Universidad de Queensland 4029, Australia. The Langton Centre, Nobbs St., Surry Hills 2010, Australia. Departamento de Farmacología y Fundación Médica, Universidad deSidney2006, Australia.
James Bell
Affiliation:
The Langton Centre, Nobbs St., Surry Hills 2010, Australia.
Macdonald J. Christie
Affiliation:
Departamento de Farmacología y Fundación Médica, Universidad deSidney2006, Australia.
Richard P. Mattick
Affiliation:
Centro Nacional de Investigación en Drogas y Alcohol, Universidad de Nueva Gales del Sur, 2052, Australia.
Get access

Resumen

La investigación indica que la buprenorfina puede poseer actividad antidepresiva. Sujetos dependientes de la heroina que recíbian mantenimiento de buprenorfina o metadona como parte de un ensayo doble ciego preexistente mayor realizado por el NDARC (Australia) rellenaron el Inventario de Depresión de Beck en la línea de base y a los tres meses. Los síntomas depresivos mejoraron en todos los sujetos, sin diferencia entre los grupos de metadona y buprenorfina, indicando que no había beneficio diferencial en los síntomas depresivos para la buprenorfina comparado con la metadona.

Keywords

BuprenorfinaAntidepresivoDepresiónDependencia de opioidesMetadona
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 12 , Issue 3 , April 2005 , pp. 185 - 191
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004;19:510-513.

References

Bibliografía

[1]Ball, JCRoss, A. Treatment success: association with patient baseline, program elements, and in-treatment process. In: Ball, JCRoss, A, editors. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991. p. 212-32.CrossRefGoogle Scholar
[2]Beck, ATWard, CHMendelson, MMock, JErbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.CrossRefGoogle ScholarPubMed
[3]Bodkin, JAZomberg, GLLukas, SECole, JO. Buprenorphine treatment of rcfractory depression. J Clin Psychopharm 1995; 15: 49–57.CrossRefGoogle Scholar
[4]Ciofalo, FR. Methadone inhibition of 3H-5:hydroxytryptamine uptake by syriaptosomes. J Pharm Exp Ther 1974; 189: 83-9.Google Scholar
[5]Darke, SHall, WWodak, AHeather, NWard, J. Development and ; validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the opiate treatment index. Brit J Add 1992;87:733 42.CrossRefGoogle ScholarPubMed
[6]Darke, SRoss, J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 2000; 95: 407-17.CrossRefGoogle ScholarPubMed
[7]De Montis, GMDevoto, P,: Tagliamonte A. Possible antidepressant activity of methadone. Eur J Pharmacol 1982; 79: 145-6.CrossRefGoogle ScholarPubMed
[8]Dilsaver, SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychopharmacol 1987; 7: 10. ,Google Scholar
[9]Emrich, HMVogt, PHerz, A. Possible antidepressant effects of opioids: action of buprenorphine. Ann N Y Acad Sci 1982;398:108-12.CrossRefGoogle ScholarPubMed
[10]Fischer, BLGRehm, JDaniel, NMedved, W. Comparing opiata users in methadone treatment with untreated opiate users: results of a follow-up study with a Toronto opiate user cohort. Can J Pub Health 1999; 90: 299–303.CrossRefGoogle ScholarPubMed
[11]Goldstein, JA. Methadone for depression. Biol Psychiat 1984; 19: 1272-3. / ‘Google ScholarPubMed
[12]Gomez-Flores, RWeber, R. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal grey. Immunopharmacology 2000; 48: 145-56.CrossRefGoogle Scholar
[13]Harris, DSMendelson, JELin, ETUpton, RAJones, RT. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokin 2004; 43: 329-40.CrossRefGoogle ScholarPubMed
[14]Huang, PKehner, GCowan, ALiu-Chen, L. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharm Exp Ther 2001; 297: 688-95.Google ScholarPubMed
[15]Kosten, TRMorgan, CKosten, TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Ab Treat 1990; 7: 514.Google ScholarPubMed
[16]Lewis, JWRanee, MJSanger, DJ. The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello, NK, editor. Advances in substance abuse. Connecticut: JAI Press; 1983. p. 103-54.Google Scholar
[17]Ling, WCharuvastra, CCollins, JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicentre, randomised clinical trial. Addiction 1998; 93: 475-86.CrossRefGoogle Scholar
[18]Mague, SDPliakas, AMTodtenkopf, MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharm Exp Ther 2003; 305: 323-30.CrossRefGoogle ScholarPubMed
[19]Mattick, RPAli, RWhite, JMO'Brien, SWolk, SDanz, C. Buprenorphine versus methadone maintenance therapy: a randomized doubleblind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441-52.CrossRefGoogle Scholar
[20]Pani, PPMaremmani, IPirastu, RTagliamonte, AGessa, GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39–50.CrossRefGoogle ScholarPubMed
[21]Petry, NMBickel, WKBadger, GJ. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice weekly dosing possible? Addiction 2000; 95: 1069-77.CrossRefGoogle ScholarPubMed
[22]Rothman, RBGorelick, DAHeishman, SJ, et al. An open-label study of a functional opioid k antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000; 18: 277-81.CrossRefGoogle Scholar
[23]Rounsaville, BJWeissman, MMCrits-Christoph, KWilber, CRleber, H. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psych 1982; 39: 151-6.CrossRefGoogle ScholarPubMed
[24]Sbrenna, SMarti, MMorari, M, et al. Modulation of 5-hydroxytryptamine eflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol 2000; 130: 425-33.CrossRefGoogle Scholar
[25]Strain, ECStitzer, MLBigelow, GE. Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis 1991; 179: 215-21.CrossRefGoogle ScholarPubMed
[26]Tejedor-Real, PMico, JAMaldonado, RRoques, BPGibert-Rahola, J. Implication of endogenous opioid System in the leamed helplessness model of depression. Pharm Biochem Behav 1995; 52: 145-52.CrossRefGoogle Scholar